Emergent Biosolutions (EBS)

$8.03 -0.06 (-0.74%)
Market Cap 417.80M
Revenue (ttm) 742.90M
Net Income (ttm) 52.60M
EPS (ttm) N/A
PE Ratio 5.33
Forward PE N/A
Profit Margin 7.08%
Debt to Equity Ratio 1.09
Volume 398,600
Avg Vol 888,874
Day's Range N/A - N/A
Shares Out 51.64M
Stochastic %K 7%
Beta 2.35
Analysts Strong Sell
Price Target $12.00

Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botul...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 240 631 3200
Fax: 240 631 3203
Address:
300 Professional Drive, Suite 400, Gaithersburg, United States
Hi_there
Hi_there Apr. 24 at 10:57 PM
$EBS well well well. What’s the news? Are they fabricating even more shit? What’s this dilution story going on…
1 · Reply
billywilliamz
billywilliamz Apr. 24 at 8:09 PM
$EBS sell the company at $15 and call it a day go private
0 · Reply
WinstonSmith33
WinstonSmith33 Apr. 24 at 8:04 PM
$EBS Actually they should print another 50M shares (+100%), not only 18M shares, because why not? They are better than shareholders and I guess they deserve it.
1 · Reply
billywilliamz
billywilliamz Apr. 24 at 7:48 PM
$EBS pinned at $8
0 · Reply
ComradeKomisar
ComradeKomisar Apr. 24 at 6:58 PM
$EBS The overhang would be 35% if that 5M shares is approved. Vote against Proposition 4.
1 · Reply
alwayzwong
alwayzwong Apr. 24 at 4:24 PM
$EBS
0 · Reply
alwayzwong
alwayzwong Apr. 24 at 4:24 PM
$EBS
0 · Reply
ImmxBeliever
ImmxBeliever Apr. 24 at 3:36 PM
$EBS adorable They will pass you have very little power, moron 
0 · Reply
Tradewind74
Tradewind74 Apr. 24 at 2:58 PM
$EBS running out of patience
0 · Reply
alwayzwong
alwayzwong Apr. 24 at 2:52 PM
$EBS testing the floor once more
2 · Reply
Latest News on EBS
Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Apr 16, 2026, 4:05 PM EDT - 8 days ago

Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Apr 16, 2026, 4:05 PM EDT - 8 days ago

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Apr 9, 2026, 4:25 PM EDT - 15 days ago

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Apr 7, 2026, 8:05 AM EDT - 18 days ago

Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

Apr 2, 2026, 8:00 AM EDT - 23 days ago

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mar 25, 2026, 4:15 PM EDT - 4 weeks ago

Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

Mar 17, 2026, 12:49 PM EDT - 5 weeks ago

Mpox Is on the Rise. 3 Vaccine Stocks Worth a Second Look.

SIGA

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Mar 3, 2026, 8:00 AM EST - 7 weeks ago

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 2 months ago

Emergent BioSolutions Earnings Call Transcript: Q4 2025

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 4:05 PM EST - 2 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Feb 26, 2026, 4:01 PM EST - 2 months ago

Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Feb 26, 2026, 4:01 PM EST - 2 months ago

Emergent BioSolutions Announces New $50 Million Stock Repurchase Program

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Feb 12, 2026, 6:00 PM EST - 2 months ago

Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 12, 2026, 9:02 AM EST - 2 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Jan 15, 2026, 1:08 PM EST - 3 months ago

NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 3 months ago

Emergent BioSolutions Transcript: 44th Annual J.P. Morgan Healthcare Conference

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Jan 12, 2026, 7:30 AM EST - 3 months ago

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Jan 8, 2026, 4:30 PM EST - 3 months ago

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Jan 8, 2026, 8:00 AM EST - 3 months ago

Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Jan 7, 2026, 7:59 AM EST - 3 months ago

Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Dec 12, 2025, 8:30 AM EST - 4 months ago

Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Nov 18, 2025, 8:00 AM EST - 5 months ago

Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Nov 12, 2025, 4:01 PM EST - 5 months ago

Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 6 months ago

Emergent BioSolutions Earnings Call Transcript: Q3 2025

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Oct 29, 2025, 4:15 PM EDT - 6 months ago

Emergent BioSolutions Reports Third Quarter 2025 Financial Results

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Oct 28, 2025, 8:00 AM EDT - 6 months ago

Emergent BioSolutions Releases New Survey Findings Revealing Heightened Concerns About Biological Threats and U.S. Preparedness

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 7:45 AM EDT - 7 months ago

Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Sep 24, 2025, 4:05 PM EDT - 7 months ago

Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Sep 19, 2025, 8:34 AM EDT - 7 months ago

Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sep 15, 2025, 8:35 AM EDT - 7 months ago

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Sep 9, 2025, 7:30 AM EDT - 8 months ago

Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Emergent BioSolutions Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 4, 2025, 3:00 PM EDT - 8 months ago

Emergent BioSolutions Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Sep 2, 2025, 7:40 AM EDT - 8 months ago

Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Aug 29, 2025, 8:05 AM EDT - 8 months ago

Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:01 AM EDT - 8 months ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Aug 21, 2025, 8:45 AM EDT - 8 months ago

Emergent BioSolutions Supports Voices for Awareness and Facing Fentanyl Now on August 21, 2025 for National Fentanyl Prevention and Awareness Day™

Emergent BioSolutions Earnings Call Transcript: Q2 2025

Aug 6, 2025, 5:00 PM EDT - 9 months ago

Emergent BioSolutions Earnings Call Transcript: Q2 2025

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:15 PM EDT - 9 months ago

Emergent BioSolutions Reports Second Quarter 2025 Financial Results

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

Jul 28, 2025, 8:50 AM EDT - 9 months ago

Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Jul 28, 2025, 8:50 AM EDT - 9 months ago

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 15, 2025, 7:30 AM EDT - 10 months ago

Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Jul 8, 2025, 4:45 PM EDT - 10 months ago

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Jul 2, 2025, 4:05 PM EDT - 10 months ago

Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Jun 23, 2025, 8:05 AM EDT - 10 months ago

Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to Bolster U.S. Biodefense Supply

Emergent BioSolutions Announces Addition to Russell 3000® Index

Jun 20, 2025, 8:13 AM EDT - 11 months ago

Emergent BioSolutions Announces Addition to Russell 3000® Index

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 1:25 PM EDT - 11 months ago

Emergent BioSolutions Transcript: Jefferies Global Healthcare Conference 2025

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Jun 5, 2025, 7:00 AM EDT - 11 months ago

Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

Emergent BioSolutions Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:35 PM EDT - 1 year ago

Emergent BioSolutions Transcript: RBC Capital Markets Global Healthcare Conference 2025

Emergent BioSolutions Earnings Call Transcript: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Emergent BioSolutions Earnings Call Transcript: Q1 2025

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 1 year ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

May 1, 2025, 5:07 PM EDT - 1 year ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Emergent BioSolutions Announces Stock Repurchase Program

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Emergent BioSolutions Announces Stock Repurchase Program

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 4:30 PM EDT - 1 year ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 20, 2025, 8:06 AM EDT - 1 year ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 13, 2025, 8:29 AM EDT - 1 year ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Emergent BioSolutions Earnings Call Transcript: Q4 2024

Mar 3, 2025, 5:00 PM EST - 1 year ago

Emergent BioSolutions Earnings Call Transcript: Q4 2024

Emergent BioSolutions Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 4:30 PM EST - 1 year ago

Emergent BioSolutions Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Emergent BioSolutions Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Emergent BioSolutions Earnings Call Transcript: Q3 2024

Emergent BioSolutions Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 10, 2024, 4:00 PM EDT - 1 year ago

Emergent BioSolutions Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Emergent BioSolutions Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 1 year ago

Emergent BioSolutions Earnings Call Transcript: Q2 2024

Emergent BioSolutions Earnings Call Transcript: Q1 2024

May 1, 2024, 5:00 PM EDT - 2 years ago

Emergent BioSolutions Earnings Call Transcript: Q1 2024

Emergent BioSolutions Earnings Call Transcript: Q4 2023

Mar 6, 2024, 5:00 PM EST - 2 years ago

Emergent BioSolutions Earnings Call Transcript: Q4 2023

Emergent BioSolutions Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 11, 2024, 12:00 PM EST - 2 years ago

Emergent BioSolutions Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Emergent BioSolutions Earnings Call Transcript: Q3 2023

Nov 8, 2023, 5:00 PM EST - 2 years ago

Emergent BioSolutions Earnings Call Transcript: Q3 2023

Emergent BioSolutions Earnings Call Transcript: Q2 2023

Aug 8, 2023, 5:00 PM EDT - 2 years ago

Emergent BioSolutions Earnings Call Transcript: Q2 2023

Emergent BioSolutions Earnings Call Transcript: Q1 2023

May 9, 2023, 5:00 PM EDT - 3 years ago

Emergent BioSolutions Earnings Call Transcript: Q1 2023

Emergent BioSolutions Earnings Call Transcript: Q4 2022

Feb 27, 2023, 5:00 PM EST - 3 years ago

Emergent BioSolutions Earnings Call Transcript: Q4 2022

Emergent BioSolutions Earnings Call Transcript: Q3 2022

Nov 8, 2022, 6:00 AM EST - 3 years ago

Emergent BioSolutions Earnings Call Transcript: Q3 2022

Emergent BioSolutions Earnings Call Transcript: Q2 2022

Jul 31, 2022, 8:45 PM EDT - 4 years ago

Emergent BioSolutions Earnings Call Transcript: Q2 2022

Emergent BioSolutions Earnings Call Transcript: Q1 2022

Apr 27, 2022, 8:00 PM EDT - 4 years ago

Emergent BioSolutions Earnings Call Transcript: Q1 2022

Emergent BioSolutions Earnings Call Transcript: Q4 2021

Feb 24, 2022, 9:22 AM EST - 4 years ago

Emergent BioSolutions Earnings Call Transcript: Q4 2021

Emergent BioSolutions Earnings Call Transcript: Q3 2021

Nov 3, 2021, 8:00 PM EDT - 4 years ago

Emergent BioSolutions Earnings Call Transcript: Q3 2021

Emergent BioSolutions Earnings Call Transcript: Q2 2021

Jul 26, 2021, 8:00 PM EDT - 5 years ago

Emergent BioSolutions Earnings Call Transcript: Q2 2021

Emergent BioSolutions Earnings Call Transcript: Q1 2021

Apr 29, 2021, 2:58 PM EDT - 5 years ago

Emergent BioSolutions Earnings Call Transcript: Q1 2021

Emergent BioSolutions Earnings Call Transcript: Q4 2020

Feb 19, 2021, 7:00 AM EST - 5 years ago

Emergent BioSolutions Earnings Call Transcript: Q4 2020

Emergent BioSolutions Transcript: 39th Annual JPMorgan Virtual Healthcare Conference

Jan 11, 2021, 8:20 AM EST - 5 years ago

Emergent BioSolutions Transcript: 39th Annual JPMorgan Virtual Healthcare Conference

Emergent BioSolutions Earnings Call Transcript: Q3 2020

Nov 5, 2020, 5:00 PM EST - 5 years ago

Emergent BioSolutions Earnings Call Transcript: Q3 2020

Emergent BioSolutions Earnings Call Transcript: Q2 2020

Jul 30, 2020, 5:00 PM EDT - 6 years ago

Emergent BioSolutions Earnings Call Transcript: Q2 2020

Emergent BioSolutions Transcript: BofA Securities 2020 Health Care Conference

May 12, 2020, 9:00 AM EDT - 6 years ago

Emergent BioSolutions Transcript: BofA Securities 2020 Health Care Conference

Emergent BioSolutions Earnings Call Transcript: Q1 2020

Apr 30, 2020, 5:00 PM EDT - 6 years ago

Emergent BioSolutions Earnings Call Transcript: Q1 2020

Emergent BioSolutions Earnings Call Transcript: Q4 2019

Feb 25, 2020, 7:00 AM EST - 6 years ago

Emergent BioSolutions Earnings Call Transcript: Q4 2019

Emergent BioSolutions Transcript: 38th Annual J.P Morgan Healthcare Conference

Jan 14, 2020, 1:30 PM EST - 6 years ago

Emergent BioSolutions Transcript: 38th Annual J.P Morgan Healthcare Conference

Emergent BioSolutions Transcript: Analyst & Investor Day 2019

Nov 21, 2019, 8:00 AM EST - 6 years ago

Emergent BioSolutions Transcript: Analyst & Investor Day 2019

Emergent BioSolutions Earnings Call Transcript: Q3 2019

Nov 6, 2019, 5:00 PM EST - 7 years ago

Emergent BioSolutions Earnings Call Transcript: Q3 2019

Emergent BioSolutions Earnings Call Transcript: Q2 2019

Aug 1, 2019, 5:00 PM EDT - 7 years ago

Emergent BioSolutions Earnings Call Transcript: Q2 2019

Emergent BioSolutions Transcript: AGM 2019

May 23, 2019, 9:00 AM EDT - 7 years ago

Emergent BioSolutions Transcript: AGM 2019

Emergent BioSolutions Earnings Call Transcript: Q1 2019

May 2, 2019, 5:00 PM EDT - 7 years ago

Emergent BioSolutions Earnings Call Transcript: Q1 2019

Hi_there
Hi_there Apr. 24 at 10:57 PM
$EBS well well well. What’s the news? Are they fabricating even more shit? What’s this dilution story going on…
1 · Reply
billywilliamz
billywilliamz Apr. 24 at 8:09 PM
$EBS sell the company at $15 and call it a day go private
0 · Reply
WinstonSmith33
WinstonSmith33 Apr. 24 at 8:04 PM
$EBS Actually they should print another 50M shares (+100%), not only 18M shares, because why not? They are better than shareholders and I guess they deserve it.
1 · Reply
billywilliamz
billywilliamz Apr. 24 at 7:48 PM
$EBS pinned at $8
0 · Reply
ComradeKomisar
ComradeKomisar Apr. 24 at 6:58 PM
$EBS The overhang would be 35% if that 5M shares is approved. Vote against Proposition 4.
1 · Reply
alwayzwong
alwayzwong Apr. 24 at 4:24 PM
$EBS
0 · Reply
alwayzwong
alwayzwong Apr. 24 at 4:24 PM
$EBS
0 · Reply
ImmxBeliever
ImmxBeliever Apr. 24 at 3:36 PM
$EBS adorable They will pass you have very little power, moron 
0 · Reply
Tradewind74
Tradewind74 Apr. 24 at 2:58 PM
$EBS running out of patience
0 · Reply
alwayzwong
alwayzwong Apr. 24 at 2:52 PM
$EBS testing the floor once more
2 · Reply
ComradeKomisar
ComradeKomisar Apr. 24 at 1:34 PM
$EBS Reminder: vote against 3 and 4. Item 3 is 'advisory' not legally binding, but it records your displeasure with performance. Last year it went down from 91% to 84%. Item 4 is legally binding. The company should not dilute for employee retention while said employees have yet to deliver a return on invested capital > cost of capital. They threated to take it in cash, and thus damage EBITDA...so be it.
1 · Reply
DragonAlgo
DragonAlgo Apr. 24 at 1:32 PM
🐉 $EBS PUT — DragonAlgo® Signal Contract: EBS PUT Expiry: 2026-05-15 | Strike: $8.00 | Type: PUT Option Plan (premium): Entry: $0.82 Stop: $0.59 TP1: $1.07 TP2: $1.39 TP3: $1.97 System-defined risk profile. 🔗 https://dragonalgo.com
0 · Reply
alwayzwong
alwayzwong Apr. 24 at 2:17 AM
$EBS wat min?
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 23 at 10:54 PM
$EBS
0 · Reply
alwayzwong
alwayzwong Apr. 23 at 8:18 PM
$EBS lol it was an honest question, been here 3 years or so. I guess people can relate lol
0 · Reply
SirTader
SirTader Apr. 23 at 8:16 PM
$EBS Think you killed the vibe in the room! LOL
0 · Reply
alwayzwong
alwayzwong Apr. 23 at 1:50 PM
$EBS question not tied to stonks— has anyone had a manager at work that micromanages everything? How did you deal with it? I’m only 2 weeks in and it’s getting tiring….
4 · Reply
billywilliamz
billywilliamz Apr. 23 at 1:39 PM
$EBS pay for thee but not for we
1 · Reply
ComradeKomisar
ComradeKomisar Apr. 22 at 11:21 PM
$EBS its either pay them with shares or cash. Cash is needed so...
2 · Reply
WinstonSmith33
WinstonSmith33 Apr. 22 at 11:13 PM
$EBS LOL they literally say that buybacks are for the management (free shares) not for shareholders. Incredible arrogance, I would fire everyone, starting from the Poor Rich man (still the same person responsible for the covid failure and price movement 140$ -> 1.40$). A bit suspicious that Papa kept these strange personalities.
0 · Reply
ComradeKomisar
ComradeKomisar Apr. 22 at 10:50 PM
$EBS I see what happened: since 80% of the share are owned by 'tutes', they rely on advisory firms on how to vote. One was "FOR", the other was "AGAINST". ISS was "AGAINST" Basically, the board is saying: there's no point paying all this cash for salaries to management, when I can earn a higher return than the 'dilly' they propose.
0 · Reply
alwayzwong
alwayzwong Apr. 22 at 10:38 PM
$EBS thanks for your take
0 · Reply